Genascence Corporation’s GNSC-001 Receives the US FDA’s Fast Track Designation for Treating Osteoarthritis (OA) of the Knee
Shots:
- The US FDA has granted Fast Track Designation to GNSC-001 for the treatment of osteoarthritis (OA) of the knee
- GNSC-001 (intra-articular) in P-I study for OA showed that it was well-tolerated, increased IL-1Ra levels in synovial fluid for 12 months, a trend favoring improved pain and function scores, and limited disease progression
- GNSC-001 is an AAV-based gene therapy delivering optimized IL-1Ra to block IL-1 signaling responsible for OA inflammation, pain & cartilage damage, offering long-term relief with a single joint injection
Ref: PR Newswire | Image: Genascence Corporation
Related News:- Caliway Biopharmaceuticals’ CBL-514 Receives the EMA’s Orphan Drug Designation for the Treatment of Dercum’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
FDA Fast Track Designation
GNSC-001
Osteoarthritis
Knee Osteoarthritis
Intra-articular injection
Phase I
IL-1Ra (Interleukin-1 Receptor Antagonist)
Synovial fluid
Pain and function scores
Disease progression
Gene therapy
AAV-based gene therapy
IL-1 signaling
Inflammation Cartilage damage
Long-term relief
Single joint injection
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
